Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis

Endocrine Journal

Volumn 45, Issue 1, 1998, Pages 97-104

  Akimoto, Susumu ^a,b   Furuya, Yuzo ^a   Akakura, Koichiro ^a   Ito, Haruo ^a  

^a CHIBA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Bone metastasis; Bone derived alkaline phosphatase; Carboxy terminal telopeptide of type I collagen (ICTP); Carboxy terminal propeptide of type I procollagen (PICP); Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; COLLAGEN TYPE 1; PROCOLLAGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PREDICTION; PROSTATE CANCER; RELIABILITY;

EID: 0031923741     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.45.97     Document Type: Article

References (27)

1. Calvo MS, Eyre DR, Gundberg CM (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17: 333-368.
2. Melkko J, Niemi S, Risteli L, Risteli J (1990) Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36: 1328-1332.
3. Francini G, Gonnelli S, Petrioli R, Bruni S, Marsili S, Aquino A, Camporeale A (1993) Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. Cancer Epidemiol, Biomarkers and Prev 2: 125-129.
4. Garnero P, Delmas P (1993) Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77: 1046-1053.
5. Panigrahi K, Delmas PD, Singer F, Ryan W, Reiss O, Fisher R, Miller PD, Mizrahi I, Darte C, Kress BC, Christenson RH (1994) Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem 40: 822-828.
6. Delmas PD, Body JJ (1992) Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 74: 471-475.
7. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L (1993) Radioimmunoassay for pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 39: 635-640.
8. Smith P H, Bono A, Calais da Silva F, Debruyne F, Denis L, Robinson P, Sylvester R, Armitage TG (1990) Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. Cancer 66: 1009-1016.
9. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202.
10. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R (1989) The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141: 873-879.
11. Hanly JA, and McNeil BJ (1983) A method of comparing the area under receiver operating characteristic curves derived from the same cases. Radiology 148: 839-843.
12. Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR (1993) Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab 76: 1452-1457.
13. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD (1994) Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 78: 955-959.
14. Kushida K, Takahashi M, Kawana K, Inoue T (1996) Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 80: 2447-2450.
15. Miyakawa M, Tsushima T, Demura H (1996) Carboxy-terminal propeptide of type I procollagen (PICP) and carboxy-terminal telopeptide of type I collagen (ICTP) as sensitive markers of bone metabolism in thyroid disease. Endocr J 43: 701-708.
16. Miyamoto KK, McSherry SA, Robins SP, Besterman JM, Mohler JL (1994) Collagen cross-linked metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol 151: 909-913.
17. Takeuchi S-I, Arai K, Saitoh H, Yoshida K-I, Miura M (1996) Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol 156: 1691-1695.
18. Pecherstorfer M, Zimmer-Roth I, Schilling T, Woitge HW, Schmidt H, Baumgartner G, Thiebaud D, Ludwig H, Seibel MJ (1995 ) The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80: 97-103.
19. Wolff JM, Ittel T, Boeckmann W, Reinike T, Habib FK, Jakse G (1996) Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer. Eur Urol 30: 302-306.
20. Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H (1996) Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 155: 1348-1351.
21. Plebani M, Bernardi D, Zaninotto M, De Paoli M, Secchiero S, Sciacovelli L (1996) New and traditional serum markers of bone metabolism in the detection of skeletal metastases. Clin Biochem 29: 67-72.
22. Withold W, Schulte U, Reinauer (1996 ) Method for determination of bone alkaline phosphatase activity: Analytical performance and clinical usefulness in patients with metabolic and malignant bone disease. Clin Chem 42: 210-217.
23. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC (1990) Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752.
24. di Sant'Agnese PA, Cockett TK (1994) The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: A review and future directions in basic research. J Urol 152: 1927-1931.
25. Deftos LJ, Nakada S, Burton DW, di Sant'Agnese PA, Cockett TK, Abrahamsson P-A (1996) Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 48: 58-62.
26. Jacobs SC (1983) Spread of prostatic cancer to bone. Urology 21: 337-344.
27. Manolagas SC, Jilka RL (1995) Bone marrow, cytokines and bone remodeling. N Engl J Med 332: 305-311.